Loading
A phase 3 trial of Trastuzumab duocarmazine, Lapatinib, Capecitabine, Trastuzumab, Vinorelbine and Eribulin in Breast cancer, run by Byondis B.V., completed.
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT03262935 by Byondis B.V., with 437 participants recorded, started 2017-12-15 and reaching its primary completion in 2021-03-31. Interventions recorded: (vic-)trastuzumab duocarmazine, Physician's choice. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
437 enrolled.
95% CI 5.4 to 7.2; Figures from the ClinicalTrials.gov results section (first posted 2023-10-19), not from a publication · 95% CI 4.0 to 5.5
Source95% CI 18.1 to 25.0; Figures from the ClinicalTrials.gov results section (first posted 2023-10-19), not from a publication · 95% CI 14.2 to 23.1
Source95% CI 22.3 to 33.7; Figures from the ClinicalTrials.gov results section (first posted 2023-10-19), not from a publication · 95% CI 21.6 to 38.4
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survivalprimary | (Vic-)Trastuzumab Duocarmazine | 291 | 7 months | 0.6401 (0.4885 to 0.8389) | 0.002 | link |
| Physician's Choice | 146 | 4.9 months | ||||
| Overall Survival | (Vic-)Trastuzumab Duocarmazine | 291 | 21 months | 0.868 (0.676 to 1.1145) | 0.236 | link |
| Physician's Choice | 146 | 19.5 months | ||||
| Objective Response Rate | (Vic-)Trastuzumab Duocarmazine | 252 | 27.8% | - | 0.732 | link |
| Physician's Choice | 122 | 29.5% |
Shares Byondis, Trastuzumab duocarmazine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Lapatinib, Capecitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Trastuzumab, Capecitabine, Breast cancer (all types) and the tag pipeline.